Coherus Oncology Inc expected to post a loss of 20 cents a share - Earnings Preview

Coherus Oncology

03/08/2026 22:55

Coherus Oncology Inc CHRS.OQ CHRS.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Redwood City California-based  company is expected to report a 40.4% increase in revenue to $14.4 million from $10.25 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Coherus Oncology Inc is for a loss of 20 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Coherus Oncology Inc is $6.50, about 351.4% above its last closing price of $1.44
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.27
-0.27
-0.25
Beat
8.5
Dec. 31 2026
-0.34
-0.34
Met
1
Sep. 30 2025
-0.29
-0.32
-0.33
Missed
-1.5​
Jun. 30 2025
-0.32
-0.30
-0.34
Missed
-14.6
​​Mar. 31 2025
-0.32
-0.23
-0.35
Missed
-50.9
Dec. 31 2024
-0.18
-0.13
-0.28
Missed
-113.1​
Sep. 30 2024
-0.16
-0.13
-0.01
Beat
92.5
Jun. 30 2024
-0.29
-0.29
-0.14
Beat
51.7
This summary was machine generated August 3 at 21:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)